Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Epstein-Barr Virus Infections 3Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Cytomegalovirus Infections 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Stomatitis 1Sezary Syndrome 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neuroblastoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

valomaciclovir 1Valacyclovir 1Rituximab 1Procalcitonin 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Infectious Mononucleosis × Valacyclovir × Clear all
NCT00274404 2011-10-27

Controlled Trial of Valacyclovir in Infectious Mononucleosis

University of Minnesota

Phase 1/2 Completed
20 enrolled

Infectious Mononucleosis, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡